← Back to Search

Biological Response Modifier

Triple therapy (MTX+SSZ+HCQ) for Rheumatoid Arthritis (TARGET Trial)

Phase 4
Waitlist Available
Led By Daniel Solomon
Research Sponsored by Brigham and Women's Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 0, 6 months
Awards & highlights

TARGET Trial Summary

This trial will compare the effects of two common RA treatments: triple therapy (sulfasalazine, methotrexate, and hydroxychloroquine) versus a TNF inhibitor (etanercept or adalimumab), plus background methotrexate for all subjects and hydroxychloroquine for subjects who were taking this at screening.

Eligible Conditions
  • Rheumatoid Arthritis

TARGET Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~0, 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 0, 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Inflammation
Secondary outcome measures
Aorta
Carotid Arteries
Change From Baseline in the Average TBR of the Index Vessel
+1 more

TARGET Trial Design

2Treatment groups
Active Control
Group I: Triple therapy (MTX+SSZ+HCQ)Active Control3 Interventions
Sulfasalazine (SSZ) 1 g bid and hydroxychloroquine (HCQ) 200 mg twice daily, not to exceed 6.5mg/kg HCQ (in addition to concomitant methotrexate [MTX]).
Group II: TNF inhibitor (etanercept or adalimumab)Active Control3 Interventions
etanercept 50 mg subcutaneously weekly or adalimumab 40 mg subcutaneously every other week (in addition to concomitant methotrexate, plus hydroxychloroquine, for subjects who were taking this at screening). Biologic treatment will be assigned randomly.

Find a Location

Who is running the clinical trial?

Brigham and Women's HospitalLead Sponsor
1,614 Previous Clinical Trials
11,470,676 Total Patients Enrolled
24 Trials studying Rheumatoid Arthritis
588,987 Patients Enrolled for Rheumatoid Arthritis
Columbia UniversityOTHER
1,433 Previous Clinical Trials
2,460,856 Total Patients Enrolled
2 Trials studying Rheumatoid Arthritis
160 Patients Enrolled for Rheumatoid Arthritis
Daniel SolomonPrincipal InvestigatorBrigham and Women's Hospital

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Treatments Against RA and Effect on FDG-PET/CT
Daniel H. Solomon, M.D.,MPH 2016. "Treatments Against RA and Effect on FDG-PET/CT". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02374021.
~18 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top